期刊文献+

HPLC法测定艾曲波帕片含量和有关物质 被引量:1

Determination of the Content and Related Substances in Eltrombopag Tablets by HPLC
下载PDF
导出
摘要 目的:建立艾曲波帕片含量测定及有关物质测定的方法。方法:采用HPLC法,色谱柱为辛烷基硅烷键合硅胶C8柱(150 mm×4.6 mm,5μm),以0.01 mol·L^-1磷酸二氢钾缓冲液(磷酸调节pH至3.0)为流动相A,乙腈为流动相B,甲醇为流动相C,梯度洗脱,流速为1.0 ml·min^-1,检测波长为230 nm,柱温为40℃,进样量为10μl。结果:在选定的色谱条件下,主成分与各杂质峰分离度良好。艾曲波帕浓度在0.1968~0.5905 mg·ml^-1范围内与峰面积有良好的线性关系(r=1.0000),平均回收率为99.5%(RSD=0.5%,n=9)。结论:该方法简便、准确、灵敏,可用于艾曲波帕片的含量和有关物质测定。 Objective:To establish a method for the determination of the content and related substances in eltrombopag tablets.Methods:An HPLC method with gradient elution was used on an octylsilane bonded silica gel C8 column(150 mm×4.6 mm,5μm).The mobile phase A was 0.01 mol·L^-1 potassium dihydrogen phosphate buffer(adjusting pH to 3.0 with phosphoric acid),the mobile phase B was acetonitrile,and the mobile phase C was methanol.The flow rate was 1.0 ml·min^-1,the detection wavelength was 230 nm,the column temperature was 40℃,and the injection volume was 10μl.Results:The related substances could be completely separated from the main component under the selected chromatographic conditions.A good linear relationship was found between the peak areas and the concentrations of eltrombopag within the range of 0.1968-0.5905 mg·ml^-1(r=1.0000)with the average recovery of 99.5%(RSD=0.5%,n=9).Conclusion:The method is simple,accurate and sensitive,and can be used for the determination of the content and related substances in eltrombopag tablets.
作者 李雪梅 易蕾 Li Xuemei;Yi Lei(Department of Pharmacy,Tianyou Hospital of Wuhan University of Science and Technology,Wuhan 430064,China)
出处 《中国药师》 CAS 2019年第11期2130-2134,共5页 China Pharmacist
关键词 艾曲波帕片 含量 有关物质 测定 高效液相色谱法 Eltrombopag tablets Content Related substances Determination HPLC
  • 相关文献

参考文献3

二级参考文献42

  • 1赵永强,王庆余,翟明,徐健,陈协群,刘文励,张梅,宋善俊,王健民,孟凡义,单渊东.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8):608-610. 被引量:102
  • 2中华医学会血液分会.成人原发免疫性血小板减少症诊治中国专家共识(修订版)[J].血栓与止血学组中华血液学杂志,2011,32(3);218.
  • 3George JN. Management of patients with refractory immune thrombocytopenic purpura [J].Thromb Haemost, 2006,4:1664.
  • 4Kojouri K, Vesely SK, Terrell DR, et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic literature review to assess longterm platelet count responses, prediction of response,and surgical complications[J].Blood, 2004,104:262.
  • 5Bertrand Godeau, Marc Michel.Treatment of chronic immune thrombocytopenic purpura in adults[J]. Ann Hematol, 2010,89(Suppll):S55.
  • 6Douglas B Cines, James B Bussel. How I treat idiopathic thrombocytopenic purpura(ITP) [J].Blood, 2005,106:22441.
  • 7Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of idiopathic throm- bocytopenic purpura in patients with persistent low platelet counts[J]. Arch Intern Med,2002,160:1630.
  • 8Dan K, Gomi S, Kuramto A,et al. A multicenter prospective study on the treatment of chronic idiopathic thrombocytopenic pupura[J]. Int J Heamtol, 1992,55:287.
  • 9Portielje JE, Westendorp EG, Kluin-Nelemans HC, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura[J]. Blood,2001,97:2549.
  • 10Vesely SK, Perdue JJ, Rizvi MA, et al. Management of adult patients with idiopathic thrombocytopenic purpura after failure of splenectomy.A systematic review[J]. Ann Int Med, 2004,140:112.

共引文献217

同被引文献8

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部